SEP 14, 2017 10:30 AM PDT
Clinical and Laboratory Studies of Zika Virus Infection
Presented at the Microbiology & Immunology 2017 Virtual Event
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: CME | P.A.C.E. CE | Florida CE
1 1 37

Speakers:
  • Associate Professor, Laboratory Medicine and Medicine / Infectious Diseases Director, UCSF-Abbott Viral Diagnostics and Discovery Center Associate Director, UCSF Clinical Microbiology Laborat
    Biography
      Dr. Charles Chiu, M.D./Ph.D., is an Assistant Professor in Laboratory Medicine and Medicine, Infectious Diseases at the University of California, San Francisco. He is also the Director of UCSF-Abbott Viral Diagnostics and Discovery Center (VDDC) at China Basin and Associate Director of the UCSF Clinical Microbiology Laboratory. Charles is an expert in the emerging field of viral metagenomics, and his research is focused on the development of microarray and deep sequencing technologies for viral pathogen discovery and clinical diagnostics. He is also the principal investigator on an R01 grant from the NIH on blood bank pathogen screening, California Discovery, UC-MEXUS, and National Research Fund for Tickborne Diseases (NRFTD) grants on the microbial epidemiology of encephalitis, diarrhea, and Lyme disease, a QB3 Rogers Family Foundation Award in translational diagnostics, and a UCSF-Abbott Viral Discovery Award. Charles has more than 30 patents and peer-reviewed publications in scientific journals and ongoing collaborations with research groups and public health agencies worldwide, including Abbott Diagnostics, Inc., Global Viral Forecasting, the United States CDC, the American Red Cross, and the Texas Biomedical Research Institute.

    Abstract:

    An unbiased metagenomic next-generation approach (mNGS) been shown to be useful in the broad identification of pathogens in clinical samples for infectious disease diagnosis, including viruses, bacteria, fungi, and parasites. This talk will discuss clinical licensed (CLIA) laboratory validation of a clinical mNGS assay for identification of pathogens in cerebrospinal fluid (CSF) and implementation of the automated SURPI computational pipeline for rapid analysis and interpretation of mNGS data. The CLIA-validated mNGS CSF test is now available as a clinical reference test for acutely ill hospitalized patients. We will also report the results from a 1-year, multi-hospital, nationwide study (“Precision Diagnosis of Acute Infectious Diseases”, June 2016 - 2017) to evaluate the clincail utility, performance, and cost-effectiveness of the mNGS assay relative to conventional microbiological testing in diagnosis of these neurological infections.  This talk will also describe new mNGS-based technologies and diagnostic platforms in development, including host response profiling to discriminate infectious versus non-infectious etiologies, antibiotic resistance determination, and nanopore sequencing, and how these approaches can be incorporated into routine clinical diagnostic testing for infectious diseases.


    Show Resources
    Loading Comments...